DOK7 and congenital myasthenic syndrome: Stimulating MuSK, either by a MuSK agonist antibody or by Dok7 overexpression, can provide therapeutic benefit in mouse models of other neuromuscular diseases, including amyotrophic lateral sclerosis, Dok7 congenital myasthenia, spinal muscular atrophy, and Emery–Dreifuss muscular dystrophy, as well as muscle wasting, sarcopenia, during aging (28, 33, 34, 39, –41).